Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry

Frank Stenner(University Hospital of Basel), Richard Cathomas(Kantonsspital Graubünden), Daniel Rauch(Washington University in St. Louis), Reinhard Zenhäusern, Urs Huber(Klinik Hirslanden), Răzvan Popescu(Hirslanden Klinik Aarau), Cyrill A. Rentsch(University of Basel), Clemens B. Caspar(Kantonsspital Baden), Daniel Betticher, Rudolf Morant, Sacha I. Rothschild(University Hospital of Basel)
Clinical Genitourinary Cancer
August 24, 2017
10.1016/j.clgc.2017.08.003
Cited by 7

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392